From Avoidance to Action: Emerging Therapies for Management of Chronic Inducible Urticaria - Episode 3
Trigger Avoidance and Antihistamine Up-Dosing in CIndU
Avoiding a trigger is the first line of defense when feasible, but many CIndU patients cannot avoid theirs, and second-generation antihistamines up-titrated to four-fold dosing often fall short.
This episode, "Trigger Avoidance and Antihistamine Up-Dosing in CIndU," features the panel examining the first steps of CIndU management and where they fall short.
Dr. Cotter asks Dr. Finklea how she approaches trigger identification and avoidance. She explains that identifying the trigger helps patients understand their disease and allows her to individualize treatment. When a trigger is avoidable, avoidance is the first line of defense. However, a patient with symptomatic dermographism cannot avoid clothing, waistbands, bra straps, or bags. A patient with heat or cold urticaria can simply skip the sauna or the cold plunge.
Provocation testing also lets clinicians measure critical thresholds and track improvement over time. Dr. Finklea gives the example of a cold urticaria patient who should not ski in Colorado if they react below 10°C. Guidelines say little beyond trying avoidance and advancing therapy if symptoms persist.
Dr. Trotter then describes her experience with second-generation H1 antihistamines as not overly positive. Following guidelines, she up-titrates to four times the standard dose. Patients with symptomatic dermographism may have the best chance of success. However, over-the-counter costs, adherence with multiple daily doses, side effects, and the prospect of indefinite treatment all limit their value.
Dr. Cotter stresses educating patients to take antihistamines proactively. Dr. Finklea up-titrates quickly, adding a dose every two to three days until reaching four-times daily dosing. Higher doses can cause dry mouth, dry eye, and sedation as drug crosses the blood-brain barrier. Context matters, so a vibratory urticaria patient might simply buy a push mower, while a long-haul truck driver needs daily therapy.
Dr. Finklea emphasizes up-titrating a single second-generation antihistamine rather than cycling or mixing agents, and avoiding first-generation agents entirely.
The next episode, "Beyond Antihistamines: Mapping CIndU Therapies to the Mast Cell," features the panel discussing a new FDA approval and positioning therapies by where they act on the mast cell.
